Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.
- DOI
- 10.1080/21645515.2024.2448882
- Published
- 2025 Dec
- Container
- Human vaccines & immunotherapeutics
- Publisher
- Taylor & Francis
- Open access
- yes
Credibility signals
uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/21645515.2024.2448882,
title = {Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.},
author = {Zhang L and Zhang Q and Liu J and Wu W and Jiang Z and Yan B and Cao Q and Liu H and Pan H and Lv J and Feng Y and Xu F and Huang S and Xu A},
year = {2025},
journal = {Human vaccines \& immunotherapeutics},
doi = {10.1080/21645515.2024.2448882},
url = {https://doi.org/10.1080/21645515.2024.2448882}
}RIS
TY - JOUR TI - Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China. AU - Zhang L AU - Zhang Q AU - Liu J AU - Wu W AU - Jiang Z AU - Yan B AU - Cao Q AU - Liu H AU - Pan H AU - Lv J AU - Feng Y AU - Xu F AU - Huang S AU - Xu A PY - 2025 JO - Human vaccines & immunotherapeutics DO - 10.1080/21645515.2024.2448882 UR - https://doi.org/10.1080/21645515.2024.2448882 ER -
APA
L, Z., Q, Z., J, L., W, W., Z, J., B, Y., Q, C., H, L., H, P., J, L., Y, F., F, X., S, H., & A, X. (2025). Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.. Human vaccines & immunotherapeutics. https://doi.org/10.1080/21645515.2024.2448882